A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00974129
Recruitment Status : Withdrawn (no subjects were enrolled, study was halted due to study staff departure)
First Posted : September 10, 2009
Last Update Posted : June 24, 2014
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

Condition or disease

Detailed Description:
This study seeks to examine a potential relationship between CTCF genotype and hemangioma size and growth rate. In addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. At each visit, patients' hemangiomas will be measured and photographed. At one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of C/T polymorphism at CTCF binding site six.

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six
Study Start Date : September 2009
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birthmarks

Patients with Infantile Hemangiomas

Biospecimen Retention:   Samples With DNA
Over the course of the study, one blood draw will be performed on each patient. This blood will be used for genetic analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients to be recruited will include infants with hemangiomas on any part of their body.

Inclusion Criteria:

  • Hemangioma must appear within one month prior to enrollment

Exclusion Criteria:

  • Hemangioma appeared before one month prior to enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00974129

United States, Connecticut
Yale Dermatology Associates
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Principal Investigator: Deepak Narayan, MD Yale University

Responsible Party: Yale University Identifier: NCT00974129     History of Changes
Other Study ID Numbers: 0507000430
First Posted: September 10, 2009    Key Record Dates
Last Update Posted: June 24, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Hemangioma, Capillary
Port-Wine Stain
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Skin Abnormalities
Congenital Abnormalities
Skin Diseases